2C2-NBOMe

2C2-NBOMe, also known as 2C-MMDA-2-NBOMe or NBOMe-MMDPEA-2, is a phenethylamine derivative from the 25-NB (NBOMe) family.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

2C2-NBOMe, also known as 2C-MMDA-2-NBOMe or NBOMe-MMDPEA-2, is a phenethylamine derivative from the 25-NB (NBOMe) family. It is the NBOMe derivative of 2C-MMDA-2 (MMDPEA-2).

It acts as a potent agonist at the serotonin 5-HT 2A receptor with weaker activity at 5-HT 2B and 5-HT 2C , and produces a head-twitch response in animal studies which often correlates with potential for psychedelic effects in humans. It is related in structure to psychedelic phenethylamine derivatives such as MMDA-2 and lophophine (MMDPEA) and is the first phenethylamine derivative with a methylenedioxy substitution on the phenyl ring but no alkyl substitution on the alpha carbon, that has been shown to produce psychedelic-appropriate responding in animals.

The drug was first described in the literature by Jason Wallach and colleagues in 2022 and 2023. It is a controlled substance in Canada under phenethylamine blanket-ban language. The drug is not an explicitly controlled substance in the United States, but could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

Substituted methoxyphenethylamine 25-NB 25C-NBOMe (NBOMe-2C-C) DMMDA MMDA (drug) MDPEA NBOMe-mescaline 2,4,6-TMPEA-NBOMe 5-APB-NBOMe

2C-MMDA-2-NBOMe - Isomer Design

Text derived from https://en.wikipedia.org/w/index.php?oldid=1367075393 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.